Toronto, Ontario--(Newsfile Corp. - August 5, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its 'smart-enabled' AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce it has completed the definitive partnership agreement with Afero, Inc.

Afero's next-generation Intelligent Edge "Smart" Platform will be embedded onto each AcuVid™ saliva test cartridge for tracking and reporting on quality assurance, shipping and logistics, as well as for point-of-care (POC) test result reporting. The Afero platform offers leading-edge, military-grade data protection, so an individual's health data is highly secure and protected, so only the health professional who has administered the test and the individual will see the results. Following the FDA-EUA approval for point-of-care use, this first-of-its-kind, the smart-enabled AcuVid™ saliva test will be submitted for FDA-EUA approval for at-home use.

"The AcuVid™ COVID-19 Rapid Antigen Saliva Test, powered by Afero, has always had the main goal of helping communities safely and securely stay open or re-open during this COVID-19 pandemic," shared Joe Britt, CEO of Afero. "Our Afero embedded solution, coupled with its encrypted Afero cloud technology, will help track and manage the AcuVid™ tests from production and manufacturing to shipping and logistics, and onto point-of-care facilities for testing and reporting. At-home testing will follow, and that's when the true power of the Afero solution will come into play by integrating with a person's health passport for test verification."

"We're pleased to finalize this agreement prior to our FDA-EUA approval for point-of-care, as we begin to ramp up our production with our current manufacturing partners," shared Rob Fia, CEO of Therma Bright. "Initially we see our smart-enabled testing solution ideal for facilities who have their own healthcare practitioners onsite and may also require a health passport for test verification for entry, such as airports, hospitals, and medical facilities, schools, businesses, stadiums and event venues. These are the places where the public come to connect for work, play or education, and are also places where people are most susceptible to catching and spreading this horrible virus and its growing list of variants."

In July 2021, Therma Bright announced that it had completed its clinical trials of its AcuVid™ COVID-19 Rapid Antigen Saliva Test for the successful detection of the Novel Coronavirus SARS CoV-2. In addition, the AcuVid™ saliva test has also successfully demonstrated its ability to detect many of the key COVID-19 variants, including the Delta B.1.617.2, P.1, P.2 and B.1.1.7 variants. Individuals will be able to use the results from this Afero smart-enabled test to demonstrate their negative COVID-19 result, via their health passport, in order to gain safe and secure access to public facilities, such as offices, restaurants and bars, airport, bus and rail stations, entertainment and sport venues, and other places where the public gather.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Afero

Backed by the fifth largest IoT patent portfolio globally, the Afero next-generation Intelligent Edge Platform gives partners an agile development process, best-in-class security, and rapid data capture across multiple products and product generations. The Afero Platform accelerates time to market, provides hardened security from devices to the cloud and from factories to customers, simplifies onboarding to help maximize customer connections, and uses semantic data relationships to streamline machine learning. The Platform is supported by elastic, multi-cloud services that deliver reliability and responsiveness, and a new software engineering model that unifies embedded, mobile, and cloud development. Afero's mobile application supports advanced quality control features and an intuitive user experience every single time a test is connected. Afero has assembled world-class mobile, hardware, security, and cloud veterans from Google, Apple, Nest, Danger, Microsoft, Amazon, Logitech, Twitter, and Netflix.

About Therma Bright Inc.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX). Visit:

Therma Bright Inc.
Rob Fia, CEO

Follow us on Twitter


Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit